Teva Pushes Fed. Circ. To Revive Seasonique Patent Suit

Law360, Washington (May 10, 2013, 6:23 PM ET) -- Teva Women's Health urged a Federal Circuit panel on Friday to revive its lawsuit against Lupin Ltd. and Mylan Inc. for their efforts to market a generic version of Teva's oral contraceptive Seasonique, claiming the lower court “was led down the wrong pathway” when it nixed the suit.

According to Teva counsel Richard C. Pettus, the company went against all prior art teachings when it formulated Seasonique, using higher doses of progesterone and estrogen than had been advised. That higher dose helped combat breakthrough bleeding, a...
To view the full article, register now.